Navigation Links
Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulation System
Date:5/21/2008

reported at

least one adverse event. Constipation and dry mouth were reported less

often in the PTNS arm compared to the tolterodine LA arm.

"PTNS provides comparable effectiveness to pharmaceuticals and may be considered an alternative to pharmacologic therapy for the treatment of OAB," Dr. Peters concluded.

In an oral presentation, "A Randomized Multi-center Study Comparing Percutaneous Tibial Nerve Stimulation with Pharmaceutical Therapy for the Treatment of Overactive Bladder," Dr. Peters presented results from a study of 100 patients conducted in 11 U.S. centers. These patients were randomized to either PTNS treatment with the Urgent PC, or to tolterodine LA. All patients in the study were diagnosed with urinary frequency at eight or more voids per day. Patients randomized into the PTNS treatment were treated weekly for 12 consecutive weeks, while patients randomized into the pharmacologic therapy were given a 90-day prescription for 4 mg daily. All patients completed voiding and bladder control diaries and questionnaires at baseline and after their 12-week follow-up.

"These results demonstrate that the Urgent PC is an effective and viable non-drug option for treating the urinary symptoms often associated with overactive bladder," said Dave Kaysen, President and Chief Executive Officer of Uroplasty, Inc. "Leading urologists across the country have been adding PTNS to their armamentarium for OAB treatment, reporting excellent outcomes and high patient satisfaction. We are delighted to have the OrBIT results validate Urgent PC's effectiveness compared to drugs and minimal side effects and expect that adoption will continue to improve, especially as additional clinical evidence emerges."

For more information about the Urgent(R) PC Neuromodulation System, please call 866-277-0466 or visit http://www.uroplasty.com.

About the Urgent PC Neuromodulation System


'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
2. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
3. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
4. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
5. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
6. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
7. Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease
8. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
9. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
11. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email: